Application and promotion of electronic comprehensive assessment and cognitive training technology for senile major depressive disorder in primary hospitals

Study on application and promotion of electronic comprehensive assessment and cognitive training technology for senile major depressive disorder in primary hospitals

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300070997

Enrollment

Unknown

Registered

2023-04-28

Start date

2023-04-28

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder in the elderly

Interventions

Intervention group:Antidepressants combined with electronic cognitive training

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: (1) Written informed consent signed by patients and their family members; (2) Age =60 years; (3) Meeting the Diagnostic criteria for single or recurrent major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders- Fifth Edition (DSM-5); (4) Currently in the acute phase, the total score of HRDS-17 at baseline was =18 (5) Symptoms of cognitive impairment, MoCA <26 (6) Primary school education or above.

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) Patients with a history of epilepsy or coronary heart disease or other serious unstable physical diseases; (2) Participated in another interventional clinical study within the past month; (3) Previous or current DSM-5 diagnosis of any of the following mental disorders: Organic mental disorders, alzheimer's disease and other causes lead to secondary causes of dementia, schizophrenia, schizoaffective disorder, bipolar disorder, delusional disorders, undifferentiated patients with mental illness, has a history of substance abuse, including with alcohol, and active drug abuse in the past 12 months, except nicotine. (4) Taking antidepressants, psychotropic drugs and other psychotropic drugs in recent 2 weeks (5) Severe aphasia, visual impairment and hearing impairment were unable to complete the scale assessment.

Design outcomes

Primary

Measure	Time frame
Change in ADAS-COG scale score from baseline at the end of 24 weeks;	—

Secondary

Measure	Time frame
Change in HAMD-17 score from baseline at each follow-up point;Changes in ADAS-COG score from baseline at each follow-up point;Change of MoCA scale score from baseline at each follow-up point;Complete response rate: Proportion of patients with HAMD-17 score =7 at each visit;Treatment response rate: the proportion of HAMD-17 score reduction rate =50% from baseline at each visit point;Change in GAD scale score from baseline at each follow-up point;Change in GDS score from baseline at each follow-up point;Change in ADL scale score from baseline at each follow-up point;Change in BSI-CV score from baseline at each follow-up point;	—

Measure

Time frame

Change in HAMD-17 score from baseline at each follow-up point;Changes in ADAS-COG score from baseline at each follow-up point;Change of MoCA scale score from baseline at each follow-up point;Complete response rate: Proportion of patients with HAMD-17 score =7 at each visit;Treatment response rate: the proportion of HAMD-17 score reduction rate =50% from baseline at each visit point;Change in GAD scale score from baseline at each follow-up point;Change in GDS score from baseline at each follow-up point;Change in ADL scale score from baseline at each follow-up point;Change in BSI-CV score from baseline at each follow-up point;

—

Countries

China

Contacts

Public ContactZhang Qinge

Beijing Anding Hospital

zqe81@126.com+86 10 58303101

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026